OTC Triptans - New Zealand
In 2009 sales of OTC triptans in New Zealand increased by 20% in current value terms to reach NZ$0.7 million.
Euromonitor International's OTC Triptans in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago and Sydney and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Euromonitor International's OTC Triptans in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the OTC Triptans market;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago and Sydney and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
OTC Triptans in New Zealand
Euromonitor International
July 2010
List of Contents and Tables
Executive Summary
Consumer Healthcare Spending Seems Not To Be Discretionary
Swine Flu Threat
Tightening Times Force Market Players To Rationalise Their Business Operations
Further Concentration in the Chemists/pharmacies Channel
Slowdown Expected, As It Is A Mature Market With High Per Capita Consumption
Key Trends and Developments
Tightening Times Accelerate the Concentration Process Amongst Market Players
Ageing Population
Recession-resistant Development
Threat of Swine Flu
Cancer and Heart Disease Are the Leading Causes of Death
Market Indicators
Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
Table 2 Life Expectancy at Birth 2004-2009
Market Data
Table 3 Sales of Consumer Health by Sector: Value 2004-2009
Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
Table 5 Consumer Health Company Shares by Value 2005-2009
Table 6 Consumer Health Brand Shares by Value 2006-2009
Table 7 Penetration of Private Label by Sector 2004-2009
Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Distribution
Generics
Vitamins & Dietary Supplements Registration and Classification
Summary 1 OTC Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
Sources
Summary 2 Research Sources
Douglas Pharmaceuticals Ltd
Strategic Direction
Key Facts
Summary 3 Douglas Pharmaceuticals Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 4 Douglas Pharmaceuticals Ltd: Competitive Position 2009
Go Healthy New Zealand Ltd
Strategic Direction
Key Facts
Summary 5 Go Healthy New Zealand Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 6 Go Healthy New Zealand Ltd: Competitive Position 2009
Mylan New Zealand Ltd
Strategic Direction
Key Facts
Summary 7 Mylan New Zealand Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 8 Mylan New Zealand Ltd: Competitive Position 2009
Red Seal Natural Health Ltd
Strategic Direction
Key Facts
Summary 9 Red Seal Natural Health Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 10 Red Seal Natural Health Ltd: Competitive Position 2009
Vitaco Health Ltd
Strategic Direction
Key Facts
Summary 11 Vitaco Health Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 12 Nutra-Life Health & Fitness (NZ) Ltd: Competitive Position 2009
Trends
Category Data
Table 12 Sales of OTC Triptans: Value 2007-2009
Table 13 Sales of OTC Triptans: % Value Growth 2007-2009
Table 14 OTC Triptans Company Shares by Value 2006-2009
Table 15 OTC Triptans Brand Shares by Value 2006-2009
Table 16 Forecast Sales of OTC Triptans: Value 2009-2014
Table 17 Forecast Sales of OTC Triptans: % Value Growth 2009-2014
Euromonitor International
July 2010
List of Contents and Tables
Executive Summary
Consumer Healthcare Spending Seems Not To Be Discretionary
Swine Flu Threat
Tightening Times Force Market Players To Rationalise Their Business Operations
Further Concentration in the Chemists/pharmacies Channel
Slowdown Expected, As It Is A Mature Market With High Per Capita Consumption
Key Trends and Developments
Tightening Times Accelerate the Concentration Process Amongst Market Players
Ageing Population
Recession-resistant Development
Threat of Swine Flu
Cancer and Heart Disease Are the Leading Causes of Death
Market Indicators
Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
Table 2 Life Expectancy at Birth 2004-2009
Market Data
Table 3 Sales of Consumer Health by Sector: Value 2004-2009
Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
Table 5 Consumer Health Company Shares by Value 2005-2009
Table 6 Consumer Health Brand Shares by Value 2006-2009
Table 7 Penetration of Private Label by Sector 2004-2009
Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Distribution
Generics
Vitamins & Dietary Supplements Registration and Classification
Summary 1 OTC Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
Sources
Summary 2 Research Sources
Douglas Pharmaceuticals Ltd
Strategic Direction
Key Facts
Summary 3 Douglas Pharmaceuticals Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 4 Douglas Pharmaceuticals Ltd: Competitive Position 2009
Go Healthy New Zealand Ltd
Strategic Direction
Key Facts
Summary 5 Go Healthy New Zealand Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 6 Go Healthy New Zealand Ltd: Competitive Position 2009
Mylan New Zealand Ltd
Strategic Direction
Key Facts
Summary 7 Mylan New Zealand Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 8 Mylan New Zealand Ltd: Competitive Position 2009
Red Seal Natural Health Ltd
Strategic Direction
Key Facts
Summary 9 Red Seal Natural Health Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 10 Red Seal Natural Health Ltd: Competitive Position 2009
Vitaco Health Ltd
Strategic Direction
Key Facts
Summary 11 Vitaco Health Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 12 Nutra-Life Health & Fitness (NZ) Ltd: Competitive Position 2009
Trends
Category Data
Table 12 Sales of OTC Triptans: Value 2007-2009
Table 13 Sales of OTC Triptans: % Value Growth 2007-2009
Table 14 OTC Triptans Company Shares by Value 2006-2009
Table 15 OTC Triptans Brand Shares by Value 2006-2009
Table 16 Forecast Sales of OTC Triptans: Value 2009-2014
Table 17 Forecast Sales of OTC Triptans: % Value Growth 2009-2014
